Latest Information Update: 19 Apr 2016
At a glance
- Originator AMI Pharm
- Mechanism of Action Cholesterol modulators; Triglyceride modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 19 Apr 2016 Preclinical trials in Undefined indication in South Korea (unspecified route) before April 2016